[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353783-105":3,"doc-detail-353783-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","occurrence-and-prognosis-of-metabolic-dysfunction-associated-steatosis-liver-disease-and-gastrointestinal-tumors-a-systematic-review-and-meta-analysis","Occurrence and prognosis of metabolic dysfunction-associated steatosis liver disease and gastrointestinal tumors - a systematic review and meta-analysis","","Background. Metabolic dysfunction-associated steatotic liver disease (MASLD) is among the most common causes of chronic liver dysfunction worldwide, and its relationship with gastrointestinal (GI) tumors remains debated. Methodology. A systematic review and meta-analysis followed a PROSPERO-registered protocol; PubMed, Cochrane Library, Web of Science, and Embase were searched through November 2025. Data extraction and quality assessment involved two investigators; hazard ratios with 95% confidence intervals were pooled in Stata. Results. Twenty-nine studies linked MASLD to colorectal polyps, colorectal cancer, esophageal cancer, gastric cancer, cholangiocarcinoma, and gallbladder cancer, with heterogeneity driven by follow-up time, methods, and country. Incidence rates and prognosis showed strong correlation. Conclusion. MASLD is significantly associated with both occurrence and prognosis of GI tumors, supporting prospective and mechanistic research.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/occurrence-and-prognosis-of-metabolic-dysfunction-associated-steatosis-liver-disease-and-gastrointestinal-tumors-a-systematic-review-and-meta-analysis/353783/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/occurrence-and-prognosis-of-metabolic-dysfunction-associated-steatosis-liver-disease-and-gastrointestinal-tumors-a-systematic-review-and-meta-analysis/353783.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of this systematic review and meta-analysis?","Question",{"text":63,"@type":64},"To quantify the relationship between MASLD and GI tumors and to evaluate how MASLD influences tumor incidence and prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which databases and time range were used for the literature search?",{"text":68,"@type":64},"PubMed, Cochrane Library, Web of Science, and Embase were searched, with the search date concluding in November 2025.",{"name":70,"@type":61,"acceptedAnswer":71},"What GI cancers were reported to be associated with MASLD?",{"text":72,"@type":64},"The meta-analysis reported associations between MASLD and colorectal polyps, colorectal cancer, esophageal cancer, gastric cancer, cholangiocarcinoma, and gallbladder cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353783,1790809699,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542",8,"Submitted 21 February 2025  \nAccepted 29 November 2025 Published 24 February 2026  \nCorresponding author  \nXinke Wang, [wangxk07@smu.edu.cn](wangxk07@smu.edu.cn)[ ](wangxk07@smu.edu.cn)Academic editor  \nFaiza Farhan  \nAdditional Information and Declarations can be found on page 19  \nDOI 10.7717/peerj.20616  \n Copyright 2026 Duan et al.  \nDistributed under  \nCreative Commons CC-BY-NC 4.0  \nOPEN ACCESS  \nOccurrence and prognosis of metabolic dysfunction-associated steatosis liver disease and gastrointestinal tumors: a systematic review and meta-analysis  \nSiyu Duan, Yiyi Wei, Zhuoyu Ding, Chaomin Pan, Li Yang, Yan Gu and Xinke Wang  \nGastroenterology, Nanfang Hospital, Guangzhou, China  \nABSTRACT  \nBackground. The metabolic dysfunction-associated steatotic liver disease (MASLD) isone of the most common causes of chronic and abnormal liver function tests globally. The relationship between metabolic MASLD and gastrointestinal tumors (GI) remains controversial.  \nMethodology. We conducted a systematic review based on a protocol registered with PROSPERO (CRD42024590389) . PubMed, Cochrane Library, Web of Science, and Embase were systematically searched until November 2025, Quality assessment and data extraction were performed by two investigators, and the hazard ratios and their corresponding 95% confidence intervals were combined using Stata for data analysis. Results. A total of 29 studies were included, we found that MASLD were related to colorectal polyps (I2 D 62.7, HR D 1.42, 95% CI [1 .22􀀕1 .66]), colorectal cancer (I2 D 82.8%, HR D 1.22, 95% CI [1 . 16􀀕1 .29]), p \u003C 0 .001) and esophagus cancer (I2 =88 .4, HRD 1. 14, 95% CI [1 .05􀀕1 .24], p \u003C 0 .001), gastric cancer (I2 D 88, HR D 1. 18, 95% CI [1 . 1􀀕 1.26]), cholangiocarcinoma (I2 D 73.7, HR D 1.26, 95% CI [1 . 1 7􀀕1 . 36], P \u003C 0 .001) and gallbladder cancer (I2 D 56. 1, HR D 1.41, 95% CI [1 .03􀀕1 .92], P \u003C 0 .001) . Factors like follow-up time, study methods and countries contributed to heterogeneity of studies. Lastly, incidence rates (IR) and prognosis of GI cancer in patients with MASLD were highly correlated.  \nConclusion. We conclude that there is a significant association and prognosis between MASLD and gastrointestinal tumors. Further studies should focus on prospective studies and mechanistic insights.  \nSubjects Gastroenterology and Hepatology, Pathology  \nKeywords MASLD, Gastrointestinal tumors, Incidence rate, Prognosis, Risk factors  \nINTRODUCTION  \nNon-alcoholic fatty liver disease (NAFLD) is a major contributor to chronic liver disease, with a global prevalence of up to 30% in adults (Rinella, 2015) . In 2020, an international consensus panel redefined NAFLD as metabolic dysfunction-associated steatotic liver disease (MASLD), also termed metabolic-associated fatty liver disease (MAFLD) (Eslam et al., 2020) . Globally, projections indicate that the number of MASLD cases in the United States and Japan could rise from approximately 83 million in 2015 to 101 million by 2030,  \nHow to cite this article Duan S, Wei Y, Ding Z, Pan C, Yang L, Gu Y, Wang X. 2026. Occurrence and prognosis of metabolic dysfunction-associated steatosis liver disease and gastrointestinal tumors: a systematic review and meta-analysis. PeerJ 14:e20616  \n[http://doi.org/10.7717/peerj.20616](http://doi.org/10.7717/peerj.20616)  \nwith up to 15 million of these in the United States and Japan combined (Fan & Li, 2023) . Despite this high prevalence, no standardized treatment regimen exists; consequently, management relies on lifestyle modification and off-label pharmacotherapy, which often fail to halt disease progression (Sun et al., 2015) . MASLD is regarded as the hepatic manifestation of metabolic syndrome (MetS) because multiple factors disturb metabolism in the liver, pancreas, adipose tissue, and skeletal muscle (Younossi, Kalligeros & Henry, 2025) . Common contributors include obesity, type 2 diabetes, and reduced health-related quality of life (Cortez-Pinto et al., 1999) .  \nGastrointes","cbCaiq397PcvA5rE","https://ap.wps.com/l/cbCaiq397PcvA5rE","pdf",2913087,25,"English","# Abstract\n## Background\n## Methodology\n## Results\n## Conclusion\n# Introduction\n## Redefinition from NAFLD to MASLD\n## Burden of GI tumors\n## Prior evidence and research gaps\n## Aim of the review\n# Survey Methodology\n## Search strategy","[{\"question\":\"What was the main purpose of this systematic review and meta-analysis?\",\"answer\":\"To quantify the relationship between MASLD and GI tumors and to evaluate how MASLD influences tumor incidence and prognosis.\"},{\"question\":\"Which databases and time range were used for the literature search?\",\"answer\":\"PubMed, Cochrane Library, Web of Science, and Embase were searched, with the search date concluding in November 2025.\"},{\"question\":\"What GI cancers were reported to be associated with MASLD?\",\"answer\":\"The meta-analysis reported associations between MASLD and colorectal polyps, colorectal cancer, esophageal cancer, gastric cancer, cholangiocarcinoma, and gallbladder cancer.\"}]","Occurrence and prognosis of metabolic dysfunction-associated steatosis liver disease and gastrointestinal tumors - a systematic review and meta-analysis | PDF",1790107226,63,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a831ef8d5f1870737fa59c8f0e1bb00e.webp",983,1272,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0459d1ac91b6ef6668f9e910b41bcad9.webp",982,1270,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ded4394bf37b230da630e0362d63666.webp",981,1269,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64ba9f0f611897824215e9798774f1fb.webp",980,1268,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":131,"slug":162},19,"General","general"]